valu usd unless otherwis note
challeng opportun
view beat ep due low effect tax rate though miss
oper line due weak margin segment compani
provid guidanc basic flat midpoint though
buoy increment contribut patient recoveri
acquisit cost cut initi continu share repurchas
ep driven tax report ep
y/i vs estim consensu beat driven
lower expect tax rate vs estim
miss op line vs compani report
top-lin beat pharmaceut segment vs
miss op vs medic segment
miss top-lin vs op line mm
vs compani also provid ep guidanc
rang expect low-singl
digit revenu growth high-single/low-doubl digit op declin
pharmaceut segment low-singl digit revenu growth mid-
high singl digit op growth medic segment
put take cardin lot sizabl move piec
impact ep expect plu side compani
expect increment accret patient recoveri growth
medic segment specialti lower tax rate lower share count
lower contribut cost save initi save
annual headwind includ divestitur china busi
divestitur major stake navihealth headwind repric
custom contract gener deflat loss pharmerica
manag problem cordi risk relat chang
wac-bas price model increment downsid risk
adjust estim lower ep
slower growth pharmaceut medic segment lower op
margin medic segment partial off-set lower sg estim
relat compani cost-cut initi lower tax rate
lower share count note ep estim low end
compani guidanc make conserv assumpt
brand gener drug price next month
maintain sector perform maintain sector perform rate
lower price target share roll forward
valuat ep lower multipl one turn reflect
increasingli limit visibl drug suppli chain pt reflect
price-to-earnings multipl appli estim
price prior trade day market close estimate unless otherwis note
cardin health one three larg drug wholesal
unit state believ share like
multipl range-bound investor get visibl
gener drug price bottom oper
earn growth resum compani
pressur last month gener drug price
deflat increas wholesal competit higher-margin
independ custom slowdown brand drug price
increas weigh result expect
backdrop improv next twelv month end
believ investor expect estim
compani core drug distribut segment bottom
could continu disappoint
estim cardin gener
profit core us drug distribut busi sale
gener drug past two year cardin seen
price gener drug deflat high singl digit mid-teen
percentag rate profit dollar contribut fall
slightli lower rate cardin grow profit gener
drug need volum growth new introduct off-set
impact drug price deflat believ
possibl gener deflat continu high singl digit
pace higher thu current environ persist
upsid risk rate includ stabil drug
price environ could caus earn estim
stabil like drive multipl expans close
outperform expect drive posit earn
gener market potenti client loss
wholesal sell side price compress
larger pharmaci custom gpo
bloomberg capit market estim upside/downside/target
price target share equal
ep estim use multipl reflect
slight discount year averag forward trade multipl
share
upsid scenario share base
ep estim higher base case price-to-earnings
multipl appli ep upsid scenario
ep better ep growth could driven
success medic devic strategi increas volum across
brand gener drug de-lever balanc sheet
level gener price deflat forward
multipl repres high end normal trade
rang drug wholes space multipl
like get neg share
downsid scenario share base
ep estim base case price-to-earnings multipl
appli ep scenario downsid scenario
ep lower expect ep could
driven hiccup implement medic devic
strategi wors expect price environ lower
expect brand gener volum forward
multipl like get posit share
result varianc tabl act commentsrevenuepharmacet profit plagu medic impair charg relat cordistot oper oper adj red oak increment benefit evaporatingmed adj total adj op incom expense- interest loss debt extinguishment- profit incom cont profit incom adjust tax benefit relat restructuringadj net ep dilut cont acq-rel discontinu op adjust ep average number share healthbp profitadj oper profit healthcar technolog distribut
price target share equal ep estim use
multipl reflect slight discount year averag forward trade multipl
share reflect challeng medic segment price target support
risk rate price target
forese upsid downsid risk sector perform rate share
upsid risk includ stabil drug price environ could caus earn
estim stabil like drive multipl expans close market multipl
cah medic surgic busi could also outperform expect drive posit
earn surpris downsid risk includ acceler drug price deterior
gener market potenti client loss wholesal sell side
price compress larger pharmaci custom gpo
healthcar servic product compani offer solut health
system pharmaci healthcar provid compani oper
medic segment busi distributor
brand gener drug specialti drug over-the-counter healthcar product
segment also provid specialti pharmaci servic china joint ventur
call red oak sourc sourc gener pharmaceut
medic busi distributor nation brand medic surgic
laboratori product healthcar provid patient home segment addit
provid profession servic healthcar provid
good sold
revenu
impair charg net
litig credit net
revenu
adj profit tax
profit tax
weight average number share
